Category

Cardiac Marker Analyzer Market Size, Share, Opportunities, And Trends By Type Of Cardiac Marker (Troponin, Creatine Kinase, Myoblobin, Others), By End User (Hospitals And Clinics, Laboratories, Ambulatory Surgical Centers), And By Geography - Forecasts From 2019 To 2024

114 pages
Published on : May 2019
Report Code : KSI061610969

Description

Cardiac marker analyzer market was valued at US$1,356.125 million in 2017 and is projected to expand at a CAGR of 4.84% over the forecast period to reach US$1,800.905 million by 2023. Cardiac market analyzer is used in the diagnosis of myocardial infarction and other cardiac-related diseases by measuring levels of various cardiac biomarkers. Rising prevalence of cardiovascular diseases owing to growing global geriatric population and lifestyle-related diseases is driving the demand for cardiac marker analyzers worldwide. Rising investments in R&D to develop innovative applications of cardiac marker analyzers and ongoing clinical trials to identify novel cardiac biomarkers will further fuel the growth of cardiac biomarker analyzer market. However, factors such as technical problems related to sample collection and regulatory and reimbursement issues are restraining the growth of cardiac marker analyzer market. Geographically, APAC will witness a significant market growth owing to the increasing cases of cardiovascular diseases and booming medical tourism industry, particularly in Southeast Asian countries. 

This research study examines the current market trends related to the demand, supply, and sales, in addition to the recent developments. Major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented in each of the geographical regions. Further, the overall regulatory framework of the market has been exhaustively covered to offer stakeholders a better understanding of the key factors affecting the overall market environment.

Identification of key industry players in the industry and their revenue contribution to the overall business or relevant segment aligned to the study have been covered as a part of competitive intelligence done through extensive secondary research. Various studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research. Both bottom-up and top down approaches have been utilized to determine the market size of the overall market and key segments. The values obtained are correlated with the primary inputs of the key stakeholders in the cardiac marker analyzer value chain. Last step involves complete market engineering which includes analyzing the data from different sources and existing proprietary datasets while using various data triangulation methods for market breakdown and forecasting.

Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining faster and efficient understanding of the Cardiac Marker Analyzer market.

Major industry players profiled as part of the report are Radiometer Medical APS, CardioGenics Inc., Roche Diagnostics International Ltd, Abbott Rapid Diagnostics, and Beckman Coulter, Inc. among others.

Segmentation

Cardiac marker analyzer market has been analyzed through following segments:

By Type of Cardiac Marker

Troponin

Creatine Kinase

Myoblobin

Others


By End User

Hospitals and Clinics

Laboratories

Ambulatory Surgical Centers


By Geography

North America

U.S.

Canada

Mexico

Others


South America

Brazil

Argentina

Others


Europe

UK

Germany

France

Others


Middle East and Africa

Saudi Arabia

UAE

Israel

Others


Asia-Pacific

Japan

China

India

Others

OUR CLIENTS